ICH Q6A, ICH Q8, FDA / EMA

Crystal Reverse Engineering

Reference Material (RLD) Q3 Microstructure Analysis and Reverse Engineering Technology

I. Core Definitions and Purpose of the Regulations

1. Crystal Reverse Engineering:

   • Definition: A technique that, without damaging the original physical state of the formulation, uses non-destructive low-temperature ion beam sample preparation combined with micro-area spectroscopy and multimodal microscopy to accurately separate, identify, and quantify the crystal form, crystal morphology, microparticle size, and microphase structure of the active pharmaceutical ingredient (API) from a reference formulation (RLD/Original Drug).

   • Physical significance: Traditional powder X-ray diffraction (PXRD) or thermal analysis (DSC) is limited by sample grinding damage and strong background interference from excipients, which easily mask trace crystallization or transformation signals. Crystal reduction engineering can objectively reduce the physical state of crystals inside the real tablet at the micron and nanometer scale, eliminating sample preparation artifacts.

2. Q3 Microstructural Equivalence of Formulation:

   • Definition: Refers to the objective arrangement of the high-level physical structure inside the formulation, including the microscopic geometry of each component (API and excipient), three-dimensional spatial distribution network, skeleton porosity, pore size distribution and interface bonding state.

   • Physical significance: The consistency of prescription composition (Q1) and proportion (Q2) does not necessarily mean consistency in in vivo absorption. The Q3 characteristic directly determines the disintegration microenvironment, solvent diffusion channels, local drug saturation solubility, and release kinetics of solid formulations. It is a core determining factor for whether generic drugs can pass in vivo bioequivalence (BE) and achieve good in vivo-in vitro correlation (IVIVC).

II. Crystal Reduction Engineering and Q3 Analysis Seven-Stage Technique

1. First stage: Sample pretreatment and non-destructive sample preparation (eliminating mechanical shearing artifacts)

• Core technology: Soft ion beam frozen section polishing technology (Cryo-BIB / Soft Ion Beam).

• Operating mechanism: Solid tablets, microspheres or freeze-dried microspheres are polished over a large area (grinding cross section > 10 mm²) under the protection of liquid nitrogen at low temperature (-120°C to -160°C).

• Technical advantages: It completely eliminates the illusions caused by frictional high temperature (thermal-induced crystallization), shearing and stretching (soft material coating to cover pores), and brittle particle breakage and detachment produced by traditional mechanical sandpaper or diamond polishing, and completely preserves the original nanopores and microcrystal boundaries of the microsphere skeleton.

2. Second stage: Preliminary screening of microstructure and coordinate positioning navigation

• Core technology: Multimodal fully automated optical navigation microscope system.

• Operating mechanism: integrates bright field, dark field, polarizing microscope (PLM), near-infrared (NIR) and transmission/reflection switching modes.

• Technical advantages: By utilizing the birefringence crystal characteristics of polarized light to initially determine the region of interest (ROI), a micron-level three-dimensional spatial coordinate navigation map is established, eliminating the need for large-area blind testing of subsequent high-vacuum electron microscopy and spectral scanning, thus significantly shortening the detection time.

3. Third Stage: Elemental Microphase Identification and Raw Material Process Analysis

• Core technologies: Field emission scanning electron microscopy (FE-SEM) + Energy dispersive X-ray spectroscopy (EDS).

• Operating mechanism: By comparing the differences in the atomic numbers of backscattered electrons (BSE) (Z-Contrast), organic matrix and various inorganic substances are distinguished, and feature element distribution (Mapping) is performed simultaneously.

• Analysis indicators:

  • Magnesium stearate (Mg): Used to determine the integrity of lubricant coating and the uniformity of mixing.

  • Talc (Mg + Si) and colloidal silica (Si): Determine the addition path and dispersion state of the flow aid.

  • Metal salt disintegrants such as carboxymethyl cellulose calcium (Ca): Determine the disintegration network framework.

  • Process retrospective analysis: By comparing the particle size and microcrack morphology of microcrystalline cellulose (MCC), lactose, and starch, it was determined that the manufacturer used dry direct tableting, wet granulation (internal/external additive ratio), or fluidized bed microcapsule coating processes.

4. Fourth stage: Directional navigation confocal microscopy Raman morphology characterization

• Core technology: Navigated Confocal Raman system for chemical imaging.

• Operating mechanism: Using API-specific coordinates calibrated by the third-stage EDS, precise micro-area positioning and sampling are performed directly with a 532 nm or 785 nm laser beam.

• Technical advantages: Reduces the traditional blind Raman scanning process of whole tablets, which takes hundreds of hours, to 2 to 3 hours; collects molecular vibration fingerprints to accurately identify whether the API is a stable crystal form, metastable crystal form, amorphous, or hydrate/solvent compound, meeting the ICH Q6A crystal form control requirements.

5. Fifth Stage: Validation of Quantitative Methods for Low-Content Mixed Crystals using Chemometrics

• Core technologies: Spectral unmixing algorithm and multivariate regression quantification.

• Operating mechanism: For trace crystalline peaks in amorphous embedded matrix, specific characteristic fingerprint peaks are extracted and intensity integration and binary/multi-element spectral unmixing calculations are performed.

• Verification indicators:

  • Limit of detection and limit of quantitation: The limit of detection (LOD) is as low as 0.1%, which can quantify trace crystallization (e.g., 1.18% residual crystals).

  • Exclusivity and interference elimination: Completely removes overlapping spectra of admixtures such as lactose, MCC, and PVP.

  • Linearity and recovery: In the range of 1.0% to 10.0% low content mixed crystals, the correlation coefficient R² ≥ 0.990, and the recovery rate falls between 90% and 110%, which fully complies with the drug regulatory declaration requirements.

6. Sixth Stage: Statistical Characterization of API Grain Abnormalities and Microparticle Size

• Core technologies: Digital image AI boundary segmentation algorithm and morphological statistical system.

• Operating mechanism: Digital identification of primary and secondary API particles embedded in the tablet is performed through aspect ratio, geometric appearance and boundary gradient.

• Analysis indicators:

  • Crystalloids are classified into four types: acicular, rod-like, plate-like, equant, and bladder-like.

  • Particle size distribution analysis: Statistics on actual particle size, agglomerated particle size, D10, D50, D90 and particle size span, solving the pain point of inconsistency between the raw material feed particle size and the actual particle size inside the tablet.

7. Phase Seven: Analysis of Complex Microspheres and Sustained-Release Formulation Q3 and its In Vitro-In Vitro Relationship (IVIVC)

• Core technology: Microstructure geometric topology algorithm (specifically for long-lasting microspheres, sustained-release coatings and matrix formulations).

• Analysis indicators:

  • Coating thickness and density: The average film thickness (µm), thickness deviation and micropore density of functional coatings (enteric/controlled release layers) were measured.

  • Microsphere porous network geometry: inscribed circle diameter (average 0.63 µm), roundness, pore length-to-width ratio, and open-pore to closed-pore ratio.

  • API spatial distribution and burst release risk warning: Analyze the API area ratio of the outer ring, middle ring and inner core using concentric rings of equal area; if the outer API concentration is significantly too high, it is the root cause of BE failure caused by burst release.

III. The Key Value of Microstructure Analysis in Generic Drug Development

1. Unravel the manufacturing black box: Determine whether the original manufacturer uses micronization, co-grinding, solid dispersion, or hot melt extrusion (HME) technology.

2. Mitigating the risk of bioequivalence (BE) failure: Ensure that the self-developed generic drug is highly consistent with the reference formulation in terms of internal porosity, crystal form uniformity, and lubricant distribution, thereby shortening the development time.

3. In response to drug regulatory reviews: Provide irrefutable data evidence for any requests submitted by FDA ANDA, EMA, TFDA, and CDE regarding "polymorphic control, trace crystallization quantification, and Q3 consistency".

IV. Qinwei Technology Perspective

In the practice of dissolution evaluation and prescription development of solid dosage forms (OSD), we often find that many generic drugs, although completely identical to the original manufacturer in terms of prescription composition (Q1) and ratio (Q2) and exhibiting highly similar general in vitro dissolution curves, face failure in clinical human bioequivalence (BE) trials.

The core root cause of this phenomenon often lies in the disconnection of the internal microscopic physical structure (Q3) of the formulation . Local displacement shear heat during tablet compression, crystal transformation caused by solvent residue during granulation, dense hydrophobic coating formed by excessive mixing of lubricants, or subtle differences in the pore topography of microspheres can all be significantly amplified in the dynamic fluid and enzyme environment of the digestive tract, leading to an irreversible shift in the drug release rate.

[Recommended by Chinwei Technology: Jieheng Technology's Crystal Reduction Engineering and Microstructure Analysis Technology]

To address the challenges in reverse engineering solid and complex microsphere formulations, Chinwei Technology recommends Jieheng Technology's pharmaceutical crystal reduction engineering and Q3 microstructure analysis technology .

• Innovative Sample Preparation and Directional Analysis: Jieheng Technology has successfully integrated large-area non-destructive sample preparation using cryo-soft ion beam polishing (Cryo-BIB) , breaking through the mechanical force crystal transfer artifacts caused by traditional grinding; and by combining FE-SEM/EDS with confocal Raman microscopy for precise directional navigation , the blind Raman spectroscopy that used to take hundreds of hours has been shortened to a few hours.

• Authoritative quantitative capability for low-content mixed crystals: It has excellent detection capability with LOD as low as 0.1%, and has established a spectroscopic demixing multiple regression quantitative methodology that meets regulatory review standards (specificity, linearity R² ≥ 0.990, recovery rate 90%–110%), providing solid data for the monitoring of trace crystal forms.

• In-depth Q3 characteristic analysis: Jieheng Technology possesses industry-leading engineering capabilities in microsphere pore geometry topology, concentric ring API spatial distribution analysis, and raw material/auxiliary material granulation path regression.

V. References and Documents

• US FDA — Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules (Guidance for Industry).

• US FDA — Draft Guidance on Doxorubicin Hydrochloride Injection (Physicochemical and Microstructural Characterization).

• ICH Q6A — Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances .

• ICH Q8(R2) — Pharmaceutical Development .

• USP <1217> Tablet Breaking Force — United States Pharmacopeia.

• EP <2.9.8> Resistance to Crushing of Tablets — European Pharmacopoeia.

• Rohrs, BR (2001). Dissolution Method Development for Poorly Soluble Compounds: Secondary Dissolution Phenomena .

• Fortunato, D. (2005). Dissolution Technologies: Critical Parameters in Filtration and Sample Preparation for Dissolution Testing .